BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
Prescription trends of key drugs of Sun Pharmaceutical Industries Ltd. in the U.S. market indicate sustained QoQ growth momentum. There is continued volume growth in key products, including Winlevi, Cequa, Ilumya and Carvedilol ER.
These products have seen a jump in prescription volume in Q4 FY22. We had seen a build-up in prescription volume from Winlevi in Q3 FY22; however, a large part of gains should be seen in Q4 FY22.
We have not seen any direct volume impact post the launch of generic version of Restasis on Cequa sales.
Sun Pharma was the first generic player to receive U.S. Food and Drug Administration approval for gAmbisome and has received competitive generic therapy exclusivity. The company is yet to launch the product in the U.S. market.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR